Open AccessP787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO‐MYELOID CLINICAL TRIAL PROGRAM
Author(s) -
Zeidan A. M.,
AlKali A.,
Borate U.,
Cluzeau T.,
DeZern A. E.,
Esteve J.,
Giagounidis A.,
Kobata K.,
Lyons R.,
Platzbecker U.,
Sallman D. A.,
Santini V.,
Sanz G. F.,
Sekeres M. A.,
Wei A. H.,
Xiao Z.,
Van Hoef M.,
NourryBoulot C.,
Sadek I.,
Ma F.,
Iordan A.,
Sabo J.,
GarciaManero G.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846032.37876.c9
Subject(s) - medicine , myelodysplastic syndromes , oncology , myeloid , myeloid leukemia , clinical trial , adverse effect , randomized controlled trial , immunology , bone marrow